Crossbow raises $77M for new cancer immunotherapies [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Crossbow Therapeutics, a cancer drugmaker developing next-generation T cell engagers, announced Wednesday it raised $77 million in a Series B round to continue studying its lead drug in the clinic. T cell engagers have become a popular investment for drugmakers and venture capitalists, who view them as an alternative to cell therapies for cancer, which can be expensive to manufacture and less convenient to administer. Several, including Johnson & Johnson's Tecvayli and Darzalex and Amgen's Imdelltra , have already been approved to treat various hematological cancers and solid tumors. But marketed T cell engagers carry a risk of immune-related side effects that can lead to serious illness or death. That's spurred companies like Crossbow to experiment with new medicines that minimize those side effects. Crossbow's technology uses antibodies that mimic T cell receptors to prompt immune cells to attack cancer cells, looking for a fragment of a protein only found on the surface of t
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Origin Materials and HP Embalagens enter PET cap distribution deal [Yahoo! Finance]Yahoo! Finance
- Barclays Sees Continued Strength in Johnson & Johnson (JNJ) Pharma Business [Yahoo! Finance]Yahoo! Finance
- Contact Lenses and Solutions Market to Reach USD 38.09 Billion by 2032 Amid Rising Vision Care Demand and Technological Advancements, Reports Vyansa Intelligence [Yahoo! Finance]Yahoo! Finance
- GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website